Novalis Biotech Incubation to invest in LS@W alumnus Cergentis

Novalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount. Cergentis, an innovative leader in genomics, provides kits and services based on its proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide. TLA enables rapid, cost-effective and complete next generation sequencing of genes of interest as well as the detection of all single nucleotide and structural variants. Cergentis recently launched TLA for complete cancer gene sequencing, reporting superior data over conventional diagnostic and gene sequencing techniques in FFPE tumour samples. source: Cergentis

Novalis Biotech Incubation to invest in LS@W alumnus Cergentis

‹ News overview